See more : FINDEX Inc. (3649.T) Income Statement Analysis – Financial Results
Complete financial analysis of Xvivo Perfusion AB (publ) (0RKL.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Xvivo Perfusion AB (publ), a leading company in the Medical – Equipment & Services industry within the Healthcare sector.
- Radiko Holdings Corp. (GEATF) Income Statement Analysis – Financial Results
- RSE Archive, LLC (REABS) Income Statement Analysis – Financial Results
- Pittards plc (PTD.L) Income Statement Analysis – Financial Results
- Gorani Industries Limited (GORANIN.BO) Income Statement Analysis – Financial Results
- Telefonaktiebolaget LM Ericsson (publ) (ERIC-A.ST) Income Statement Analysis – Financial Results
Xvivo Perfusion AB (publ) (0RKL.L)
About Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 597.54M | 415.29M | 258.39M | 179.86M | 220.84M | 187.87M | 148.34M | 138.18M | 120.25M | 84.70M | 68.92M | 14.72M |
| Cost of Revenue | 152.43M | 118.34M | 70.11M | 46.89M | 58.02M | 51.92M | 34.95M | 35.94M | 35.29M | 20.66M | 14.79M | 3.31M |
| Gross Profit | 445.11M | 296.96M | 188.28M | 132.98M | 162.81M | 135.95M | 113.40M | 102.24M | 84.96M | 64.05M | 54.14M | 11.41M |
| Gross Profit Ratio | 74.49% | 71.51% | 72.87% | 73.93% | 73.73% | 72.37% | 76.44% | 73.99% | 70.66% | 75.61% | 78.55% | 77.51% |
| Research & Development | 135.94M | 69.34M | 54.04M | 56.18M | 62.65M | 47.93M | 39.47M | 36.67M | 31.09M | 23.92M | 15.19M | 2.31M |
| General & Administrative | 76.94M | 70.98M | 55.69M | 30.34M | 24.74M | 22.52M | 20.05M | 24.49M | 13.15M | 11.10M | 12.02M | 5.66M |
| Selling & Marketing | 232.26M | 152.40M | 97.69M | 59.90M | 60.79M | 47.95M | 43.70M | 35.71M | 32.05M | 22.67M | 17.05M | 3.25M |
| SG&A | 309.21M | 223.38M | 153.38M | 90.24M | 85.53M | 70.47M | 63.75M | 60.20M | 45.21M | 33.77M | 29.07M | 8.91M |
| Other Expenses | -4.22M | -219.00K | -393.00K | 20.87M | 10.67M | 4.08M | 2.88M | 2.04M | 537.00K | -726.00K | -395.00K | 0.00 |
| Operating Expenses | 440.92M | 292.50M | 207.02M | 167.29M | 158.84M | 122.47M | 106.10M | 98.90M | 76.83M | 56.97M | 43.87M | 11.22M |
| Cost & Expenses | 593.36M | 410.84M | 277.13M | 214.17M | 216.87M | 174.39M | 141.04M | 134.85M | 112.11M | 77.62M | 58.65M | 14.51M |
| Interest Income | 8.85M | 2.12M | 276.00K | 80.00K | 469.00K | 449.00K | 21.00K | 48.00K | 6.00K | 3.00K | 0.00 | |
| Interest Expense | 1.19M | 605.00K | 276.00K | 361.00K | 285.00K | 128.00K | 101.00K | 100.00K | 189.00K | 123.00K | 0.00 | |
| Depreciation & Amortization | 76.35M | 15.80M | 32.26M | 13.37M | 11.17M | 6.77M | 14.92M | 13.22M | 11.64M | 4.73M | 2.18M | 1.31M |
| EBITDA | 126.57M | 39.21M | 39.20M | -43.33M | 16.81M | 20.25M | 22.37M | 16.21M | 19.14M | 11.63M | 12.25M | 799.00K |
| EBITDA Ratio | 21.18% | 15.74% | 15.19% | -9.45% | 13.81% | 18.39% | 15.17% | 11.81% | 15.91% | 13.73% | 17.78% | 1.44% |
| Operating Income | 38.51M | 23.18M | 6.98M | -34.31M | 5.63M | 14.00M | 7.11M | 2.73M | 7.21M | 6.69M | 10.77M | 212.00K |
| Operating Income Ratio | 6.44% | 5.58% | 2.70% | -19.08% | 2.55% | 7.45% | 4.79% | 1.98% | 6.00% | 7.90% | 15.63% | 1.44% |
| Total Other Income/Expenses | 56.02M | -867.00K | -317.00K | -11.59M | 1.35M | 3.50M | 346.00K | 259.00K | 186.00K | -774.00K | -56.00K | -50.00K |
| Income Before Tax | 94.52M | 22.31M | 6.67M | -57.26M | 5.29M | 17.50M | 7.45M | 2.99M | 7.40M | 6.72M | 10.72M | 139.00K |
| Income Before Tax Ratio | 15.82% | 5.37% | 2.58% | -31.84% | 2.40% | 9.31% | 5.02% | 2.17% | 6.15% | 7.93% | 15.55% | 0.94% |
| Income Tax Expense | 2.70M | 3.89M | -1.49M | -13.53M | 351.00K | 4.81M | 1.19M | 1.49M | 2.27M | 2.98M | 2.66M | 908.00K |
| Net Income | 91.82M | 18.43M | 8.15M | -43.74M | 4.94M | 12.69M | 6.26M | 1.50M | 5.13M | 3.74M | 8.05M | -769.00K |
| Net Income Ratio | 15.37% | 4.44% | 3.15% | -24.32% | 2.24% | 6.75% | 4.22% | 1.09% | 4.27% | 4.41% | 11.69% | -5.22% |
| EPS | 3.07 | 0.62 | 0.28 | -1.61 | 0.19 | 0.48 | 0.25 | 0.07 | 0.24 | 0.25 | 0.41 | -0.04 |
| EPS Diluted | 3.07 | 0.62 | 0.28 | -1.61 | 0.18 | 0.48 | 0.24 | 0.07 | 0.24 | 0.25 | 0.41 | -0.04 |
| Weighted Avg Shares Out | 29.94M | 29.53M | 28.85M | 27.17M | 26.52M | 26.30M | 25.44M | 22.57M | 21.51M | 20.54M | 19.56M | 19.56M |
| Weighted Avg Shares Out (Dil) | 29.94M | 29.53M | 28.94M | 27.17M | 26.80M | 26.30M | 25.69M | 22.78M | 21.56M | 20.73M | 19.56M | 19.56M |
Source: https://incomestatements.info
Category: Stock Reports